2135 completed, 608 terminated, 544 recruiting, 409 unknown. 2013 Phase 2, 1297 Phase 1, 429 Phase 3, 299 Not applicable, 91 Phase 4.
Follow Bone Marrow Diseases: new trials by email Literature Review of Bone Marrow Diseases trials Research Report on Bone Marrow Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Methadone as an Alternative Treatment for Children Underdoing HSCT PCA plus methadone (Experimental), PCA Alone (SOC) - Leukemia, Aplastic Anemia | Phase 3 | Suspended | University of Texas Southwestern Medical Center | 60 | 2028-01-01 | 2025-10-23 |
| Prenatal Transplantation for Fetuses With Fanconi Anemia IUHSCT for FA-affected fetuses - Fanconi Anemia, Anemia, Hypoplastic, Congenital | Phase 1 / Phase 2 | Not yet recruiting | Agnieszka Czechowicz | 12 | 2028-01-01 | 2026-06-16 |
| Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®) - Aplastic Anaemia | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 59 | 2027-08-01 | 2026-10-21 |
| A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS) Roxadustat, Placebo - Myelodysplastic Syndromes | Phase 3 | Not yet recruiting | Kyntra Bio | 201 | 2027-04-01 | 2026-07-23 |
| A Study of Rusfertide in Adults With Polycythemia Vera in China Rusfertide - Polycythemia Vera | Phase 2 | Not yet recruiting | Takeda | 24 | 2027-03-01 | 2026-08-28 |
| Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT imetelstat - High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 27 | 2027-02-01 | 2026-11-02 |
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome Busulfan, Melphalan, Fludarabine - Myelodysplastic Syndromes, Graft Vs Host Disease | Not applicable | Not yet recruiting | Guenther Koehne | 62 | 2027-01-01 | 2026-10-13 |
| WELL-MPN: A Digital Lifestyle App for Patients With MPNs WELL-MPN Digital App - Myeloproliferative Neoplasms (MPNs) | Not applicable | Not yet recruiting | Brigham and Women's Hospital | 75 | 2027-01-01 | 2026-09-29 |
| A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) BLEX 404 Oral Liquid - Myelodysplastic Syndrome (MDS) | Phase 2 | Not yet recruiting | BioLite, Inc. | 52 | 2027-01-01 | 2026-04-13 |
| Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome Monzosertib, Posaconazole, Isavuconazole - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 42 | 2027-01-01 | 2026-08-21 |
| Asciminib Frontline Risk Adapted Dasatinib 80mg QD (5 days per week), Standarc of Care - Chronic Myeloid Leukemia (CML) | Phase 2 | Not yet recruiting | Prof. Dr. med. Andreas Hochhaus | 200 | 2027-01-01 | 2026-09-04 |
| Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase | Phase 2 | Not yet recruiting | John Mascarenhas | 20 | 2027-01-01 | 2026-10-14 |
| Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris NM8074, Soliris - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-01-01 | 2026-04-13 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS) Allogeneic umbilical cord mesenchymal stem cells, Decitabine - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Suspended | Sclnow Biotechnology Co., Ltd. | 40 | 2026-12-31 | 2026-04-23 |
| A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs ELVN-001, TKI - Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Not yet recruiting | Enliven Therapeutics | 450 | 2026-12-31 | 2026-10-29 |
| A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Emavusertib - Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 270 | 2026-12-18 | 2026-09-22 |
| A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH. FXS6837 Capsule, Eculizumab infusion - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 90 | 2026-12-10 | 2026-08-05 |
| CK0801 for Treatment of Aplastic Anemia CK0801 - Aplastic Anemia | Phase 2 | Not yet recruiting | Cellenkos, Inc. | 12 | 2026-12-03 | 2026-10-20 |
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
Showing 20 of 4329. Sign in to see all of them.
Myelodysplastic Syndromes (1969) · Leukemia, Myeloid, Acute (1494) · Leukemia (916) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (878) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (807) · Myeloproliferative Disorders (664) · Primary Myelofibrosis (620) · Leukemia, Myelomonocytic, Chronic (540) · Lymphoma, Non-Hodgkin (473) · Multiple Myeloma (451) · Leukemia, Lymphocytic, Chronic, B-Cell (447) · Leukemia, Myeloid, Chronic-Phase (439) · Hodgkin Disease (417) · Lymphoma (386) · Blast Crisis (356)
Hemic and Lymphatic Diseases (4327) · Hematologic Diseases (4217) · Neoplasms (2793) · Neoplasms by Histologic Type (2692) · Leukemia, Myeloid (2367) · Pathological Conditions, Signs and Symptoms (1875) · Pathologic Processes (1841) · Disease Attributes (1770) · Leukemia (1716) · Chronic Disease (1686) · Myeloproliferative Disorders (1572) · Immune System Diseases (1233) · Immunoproliferative Disorders (1120) · Lymphatic Diseases (1102)
Cyclophosphamide (375) · fludarabine phosphate (296) · Azacitidine (268) · fludarabine (251) · Cytarabine (250) · Busulfan (235) · Whole-Body Irradiation (195) · Cyclosporine (190) · Mycophenolic Acid (190) · Peripheral Blood Stem Cell Transplantation (182) · Tacrolimus (180) · Imatinib Mesylate (175) · Antilymphocyte Serum (174) · Filgrastim (164) · ruxolitinib (151)
M.D. Anderson Cancer Center (253) · Novartis Pharmaceuticals (184) · National Cancer Institute (NCI) (163) · Fred Hutchinson Cancer Center (146) · National Heart, Lung, and Blood Institute (NHLBI) (87) · Memorial Sloan Kettering Cancer Center (77) · Masonic Cancer Center, University of Minnesota (67) · Bristol-Myers Squibb (56) · City of Hope Medical Center (56) · Celgene (53) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (45) · Incyte Corporation (37) · Washington University School of Medicine (36) · Institute of Hematology & Blood Diseases Hospital, China (35) · Case Comprehensive Cancer Center (34)
United States (2609) · France (504) · Italy (439) · Germany (409) · China (363) · United Kingdom (335) · Canada (314) · Spain (299) · Australia (219) · South Korea (217) · Belgium (184) · Netherlands (161) · Japan (151) · Poland (148) · Israel (131)
Jorge Cortes, MD (23) · Guillermo Garcia-Manero, MD (18) · Brenda Sandmaier (17) · John Mascarenhas, MD (16) · Neal S Young, M.D. (12) · Ronald Hoffman, MD (12)
PMID 32499241, PMID 24383844, PMID 25527568, PMID 34724566, PMID 35235189, PMID 23524640, PMID 23620574, PMID 28835440, PMID 30885996, PMID 31375516, PMID 42013378, PMID 23065508, PMID 27400247, PMID 29674506, PMID 25361995, PMID 29958797, PMID 35982483, PMID 36184192, PMID 37042865, PMID 39516087, PMID 16609072, PMID 18997171, PMID 20965785, PMID 21403127, PMID 22430088, PMID 22825216, PMID 25310303, PMID 27658437, PMID 30504345, PMID 34699069, PMID 35007144, PMID 37553873, PMID 39079163, PMID 39535306, PMID 40073835, PMID 40535755, PMID 40694294, PMID 41758981, PMID 41958363, PMID 42316774, PMID 1090310, PMID 16775234, PMID 17021321, PMID 17151364, PMID 17715389, PMID 18379007, PMID 19179301, PMID 19230772, PMID 19546476, PMID 19797518
P30CA015704 (60), P30CA033572 (38), 2023 (36), P30CA006973 (35), P30CA016672 (23), 2018 (22), P30CA043703 (22), 2016 (20), 2017 (20), P01CA018029 (20), U01CA070095 (20), U10CA032102 (20), 2015 (19), 2014 (18), 2019 (17)